$2.11 Billion
The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.$20.7 Million
Total revenue in the last quarter.$-11 Million
Net income is all revenues minus all expenses including taxes and interest in the last quarter.$-0.62
Earnings per share is the amount of net income that is attributed to each single share outstanding.-
Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).-60.05x
The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.$-11.1 Million
Earnings before interest expenses and taxes in the last quarter.354
The number of full time employees.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
BidaskClub cut shares of Veracyte (NASDAQ:VCYT) from a strong-buy rating to a buy rating in a report issued on Friday, BidAskClub reports. Other equities analysts also recently issued research repo...
Shares of Veracyte, Inc. (NASDAQ:VCYT) have been assigned a consensus rating of “Hold” from the seven analysts that are presently covering the company, MarketBeat reports. Two analysts have rated t...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting
